Physician profile
Sammy Saab
NPI 1720008899
$1,917,306.46
in general payments reported to CMS, 2019-2025
37 companies · $368K in 2025
The $368K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464K · 2020: $135K · 2021: $211K · 2022: $234K · 2023: $262K · 2024: $243K · 2025: $368K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $577K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $129K · Travel and Lodging: $71K · Consulting Fee: $69K · Food and Beverage: $22K · Honoraria: $5,523 · Education: $68.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $576,860.95 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $128,700.00 |
| Travel and Lodging | $71,328.78 |
| Consulting Fee | $68,936.50 |
| Food and Beverage | $21,501.28 |
| Honoraria | $5,523.00 |
| Education | $68.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $514,028.47 | 2019-2025 | Xifaxan, Xifaxan |
| Gilead Sciences, INC. | $445,806.19 | 2019-2025 | Epclusa, Vemlidy, Livdelzi |
| Mallinckrodt Hospital Products INC. | $165,479.19 | 2020-2025 | Terlivaz |
| Madrigal Pharmaceuticals | $150,850.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $133,840.07 | 2019-2025 | Mavyret |
| Ipsen Biopharmaceuticals, INC | $79,402.10 | 2024-2025 | Iqirvo, Bylvay |
| Eisai INC. | $64,158.69 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $61,768.55 | 2019-2025 | Ocaliva |
| Exelixis INC. | $59,263.22 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54,733.74 | 2022-2024 | Livtencity |
| Dova Pharmaceuticals | $54,527.85 | 2019-2021 | |
| Novo Nordisk INC | $36,257.46 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,903.77 | 2024-2025 | |
| Shionogi INC | $16,236.89 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15,190.83 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Swedish Orphan Biovitrum Ab | $12,580.00 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $11,791.77 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $5,563.00 | 2019 | |
| Glaxosmithkline, LLC. | $3,432.34 | 2024-2025 | |
| Orphalan INC | $3,244.66 | 2023-2025 | Cuvrior |
| Eton Pharmaceuticals, INC. | $3,000.00 | 2025 | Nitisinone, Betaine Anhydrous, Carglumic Acid |
| Pfizer INC. | $2,645.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $1,900.00 | 2023 | |
| W. L. Gore & Associates, INC. | $1,608.68 | 2022-2025 | Gore Viatorr Tips Endoprosthesis With Controlled Expansion, Gore Tag Conformable Thoracic Endoprosthesis, Gore Cardioform Septal Occluder |
| Bausch Health US, LLC | $800.00 | 2025 | |
| Alnylam Pharmaceuticals INC. | $774.48 | 2022-2025 | Givlaari, Oxlumo |
| Janssen Pharmaceuticals, INC | $500.00 | 2019-2020 | |
| Mirum Pharmaceuticals, INC. | $422.14 | 2023-2025 | Livmarli, Chenodal, Cholbam |
| Sequana Medical US INC. | $167.46 | 2025 | Alfapump System |
| Lilly USA, LLC | $165.66 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $79.37 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $58.60 | 2024 | Utaswako Afp-L3 |
| Eiger Biopharmaceuticals, INC. | $50.39 | 2022-2023 | Zokinvy |
| Echosens North America, INC. | $44.94 | 2025 | Fibroscan |
| Agios Pharmaceuticals, INC. | $22.89 | 2023 | Pyrukynd |
| Travere Therapeutics, INC. | $7.89 | 2023 | Cholbam |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sammy Saab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.